FDA approves Novavax COVID vaccine with new conditions

The FDA has approved Novavax's COVID-19 vaccine, Nuvaxovid, but with restrictions. It's authorized for individuals 65 and older, and those aged 12-64 with underlying conditions increasing their risk of severe COVID-19. Pediatric studies for children under 12 are still pending. The approval marks a significant step for Novavax, despite earlier delays attributed to the vaccine's composition.